Subtype
Urinary System Adenocarcinoma
CI-CAN-00004181Explore in graph →
378 active trials17 approved drugs60 evidence items
- NCIt
- C224634
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004181Explore in graph →
Clinical trials
1,629 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (279)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00019396 | flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00019539 | Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03012581 | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types(AcSé) | completed | Phase 2 | 269 | UNICANCEROTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | completed | Phase 1 / Phase 2 | 263 | Pharmacyclics LLC.INDUSTRY | 4 | Nov 18, 2023 | clinicaltrials |
| NCT03680521 | Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | completed | Phase 2 | 25 | Mirati Therapeutics Inc.INDUSTRY | 1 | Oct 4, 2023 | clinicaltrials |
| NCT01517243 | Phase II Study of Alternating Sunitinib and Temsirolimus | completed | Phase 2 | 37 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | completed | Phase 2 | 37 | University of FloridaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT03200717 | Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment(IO-PAZ) | completed | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 21, 2023 | clinicaltrials |
| NCT02855203 | Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours(RAPPORT) | completed | Phase 1 / Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT01689766 | Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma | completed | Phase 2 | 150 | EndocyteINDUSTRY | 1 | Jul 25, 2023 | clinicaltrials |
| NCT03679767 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | completed | Phase 2 | 121 | Incyte CorporationINDUSTRY | 8 | Jul 21, 2023 | clinicaltrials |
| NCT00068393 | Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma | completed | Phase 2 | 39 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 7, 2023 | clinicaltrials |
| NCT02579811 | Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer | completed | Phase 2 | 40 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01689662 | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma | completed | Phase 2 | 40 | EndocyteINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04535687 | Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma | completed | Phase 2 | 1 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02853344 | Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) | completed | Phase 2 | 275 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 11, 2023 | clinicaltrials |
| NCT03428217 | CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma(CANTATA) | completed | Phase 2 | 444 | Calithera Biosciences, IncINDUSTRY | 8 | Mar 20, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT00830895 | RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC) | completed | Phase 2 | 49 | Seoul National University HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT00142415 | Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer | completed | Phase 1 / Phase 2 | 26 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02917772 | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma(TITAN-RCC) | completed | Phase 2 | 200 | AIO-Studien-gGmbHOTHER | 8 | Oct 6, 2022 | clinicaltrials |
| NCT03163667 | CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)(ENTRATA) | completed | Phase 2 | 69 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 15, 2022 | clinicaltrials |
| NCT02348008 | Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma: | completed | Phase 1 / Phase 2 | 61 | Arkadiusz Z. Dudek, MDOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT02089685 | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | completed | Phase 1 / Phase 2 | 295 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 13, 2022 | clinicaltrials |
| NCT02489695 | Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma(AXIPAP) | completed | Phase 2 | 44 | Centre Leon BerardOTHER | 1 | Sep 6, 2022 | clinicaltrials |
| NCT02432846 | Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)(MERECA) | completed | Phase 2 | 88 | MendusINDUSTRY | 9 | Aug 22, 2022 | clinicaltrials |
| NCT01034631 | BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 154 | Hoosier Cancer Research NetworkOTHER | 3 | Jul 11, 2022 | clinicaltrials |
| NCT03029780 | An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma(CheckMate 800) | completed | Phase 2 | 104 | Bristol-Myers SquibbINDUSTRY | 3 | Jun 29, 2022 | clinicaltrials |
| NCT01157091 | Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer | completed | Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT01664182 | Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2022 | clinicaltrials |
| NCT01354431 | BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC) | completed | Phase 2 | 168 | Bristol-Myers SquibbINDUSTRY | 4 | May 12, 2022 | clinicaltrials |
| NCT00126672 | RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT01513187 | Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 53 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT00112840 | CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2022 | clinicaltrials |
| NCT01399918 | Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) | completed | Phase 2 | 57 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT01566747 | Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 | completed | Phase 2 | 43 | Cancer Trials IrelandNETWORK | 2 | Dec 23, 2021 | clinicaltrials |
| NCT03136627 | Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC | completed | Phase 1 / Phase 2 | 28 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 6, 2021 | clinicaltrials |
| NCT03430895 | Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract | completed | Phase 2 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT00550277 | LBH589 Treatment for Refractory Clear Cell Renal Carcinoma | completed | Phase 2 | 20 | SCRI Development Innovations, LLCOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT03013335 | Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen(NIVOREN) | completed | Phase 2 | 730 | UNICANCEROTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03339219 | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma | completed | Phase 2 | 35 | TakedaINDUSTRY | 1 | Sep 20, 2021 | clinicaltrials |
| NCT02599779 | A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients(OZM-065) | completed | Phase 2 | 4 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT01896271 | High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer | completed | Phase 2 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT01024920 | Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. | completed | Phase 2 | 99 | Boehringer IngelheimINDUSTRY | 5 | Jul 19, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Mar 4, 2024source: clinicaltrials